ARTICLE | Company News
Genor Biopharma, RuiYi deal
May 20, 2013 7:00 AM UTC
RuiYi granted Genor exclusive rights to develop and commercialize RYI-008 ( ARGX-109) in China. RYI-008, an anti-IL-6 mAb, is in preclinical development for cancer and autoimmune indications. RuiYi s...